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ASSESSING EFFECT OF MEDICATION ADHERENCE AND PERSISTENCE ON
COST-EFFECTIVENESS
AD1
COMPLIANCE MEASUREMENT USING ADMINISTRATIVE DATA FROM GERMAN
SICKNESS FUNDS
Frey S, Stargardt T
University of Hamburg, Hamburg, Germany
OBJECTIVES: To compare refill compliance and refill persistence measures as to
their accuracy in identifying patients with schizophrenia at risk of temporary
discontinuance or complete cessation of antipsychotic pharmacotherapy.
METHODS: Data was obtained from three German sickness funds with approxi-
mately 7 million insured (9.9% of SHI members). Information on age, sex, prescrip-
tion related information and hospitalization were collected. A total of 1484 patients
with schizophrenia (ICD-10 F20) who were treated in hospital and subsequently
received antipsychotic long-term pharmacotherapy were evaluated. Refill compli-
ance measures based on single-interval availability, multiple-interval availability,
as well as refill persistence were calculated for each patient over one year. The
resulting 10 derivative measures were compared with respect to their performance
in predicting six-month rehospitalization using multivariate logistic regression.
C-statistics were calculated to determine each model’s predictive performance.
RESULTS: Likelihood ratio tests showed that the inclusion of a compliance variable
significantly improved the predictive performance in six out of ten models over the
baseline model with age, sex and severity (p0.05). Refill compliance as a contin-
uous variable of medication persistence including transfer of oversupplies into
subsequent periods, performed best in predicting rehospitalization (C0.669).
Availability ratios capped at 100% were superior to default availability ratios in
predicting rehospitalization. Allowing for cross-period carryover improved the dis-
criminatory performance of our persistence models. CONCLUSIONS: Persistence
measures appear sufficiently flexible to account for interruptive events, i.e. hospi-
talization, common in schizophrenia and other psychiatric diseases. It is recom-
mended to use a continuous refill persistence measure to assess compliance in
psychiatric conditions when working with administrative data.
AD2
COST-CONSEQUENCE ANALYSIS OF SWITCHING FROM AN ORAL
ANTIPSYCHOTIC TO LONG ACTING INJECTABLE RISPERIDONE AMONG
PATIENTS WITH SCHIZOPHRENIA
Degli Esposti L, Sangiorgi D, Buda S
CliCon Srl, Ravenna, Italy
OBJECTIVES: Lack in treatment adherence in schizophrenia often leads to an in-
crease of relapses and, consequentially, to an increase for direct health care costs
(eg, hospitalizations). The aim of the SMART study (Schizophrenia Medications
Adherence: long-acting Risperidone versus other Therapies) is to assess the varia-
tion in total health-related costs among schizophrenic patients switching from oral
antipsychotics to Long Acting Injectable Risperidone (LAI-R). METHODS: A multi-
center, retrospective observational cohort study based on Local Health Units ad-
ministrative databases was conducted. Patients with a diagnosis of Schizophrenia,
schizotypal and delusional disorders, with a first prescription of LAI-R between
January 1, 2007 and December 31, 2008 and a previous treatment with oral antip-
sychotics were enrolled. Direct medical costs (drugs, hospitalizations, Department
of Mental Health services, outpatient specialist services) were evaluated during the
12 months preceding and following the date of inclusion. RESULTS: A total of 116
patients were enrolled, 57 male and 59 female, aged 4917 years old. Total average
disease-related cost per patient was €5.003,49 during the period preceding LAI-R
and €4.138,62 during the LAI-R period (-€864,88, -17%, p0.021). The cost increase
for antipsychotic drugs (from €291.41 to €2445.94, p0.001) was offset by a cost
reduction for semi-residentiality (from €276.69 to €23.78, p0.884), residentiality
(from €2,669.90 to €831.52, p0.004), Department of Mental Health services (from
€77.25 to €479.88, p0.001) and hospitalizations (from €1723.67 to €772.61, p0.005);
we registered a decrease in mean length of stay (LOS) (from 4.1 days to 1.2, p0.002)
and in the number of hospitalizations per patient (from 0.27 to 0.08, p0.001); 24%
patients were hospitalized during the period preceding LAI-R and 8% during the
LAI-R period. Moreover, the cost for services not related to schizophrenia showed a
slight reduction (from €1318.78 to €1016.62, p0.417). CONCLUSIONS: This thera-
peutic strategy appears to be cost saving, especially with regard to the reduction in
hospitalizations.
AD3
ASSESSING THE COMPLIANCE AND PERSISTENCE OF ALLERGEN
IMMUNOTHERAPY IN ALLERGIC RHINITIS USING A RETROSPECTIVE
PHARMACY DATABASE FROM THE NETHERLANDS
Kiel MA1, Gerth van Wijk R2, Röder E2, Al MJ1, Hop WC2, Rutten-van Mölken MP1
1Erasmus University, Rotterdam, The Netherlands, 2Erasmus Medical Center, Rotterdam, The
Netherlands
OBJECTIVES: Long-term compliance and persistence has been poorly assessed in
allergen immunotherapy for allergic rhinitis, a frequently applied but costly (€1543/
year, 2009 figures), treatment for an increasingly prevalent disease. Allergen im-
munotherapy with pollen and/or mites requires a three to five year long course of
treatment. Immunotherapy may be administered sublingually(SLIT) at home, or
subcutaneously(SCIT) at the doctor’s office. This study aims to assess the long-term
compliance and persistence of allergen immunotherapy and the costs of prema-
ture cessation of immunotherapy. METHODS: Data from over 8,000 users who
started allergen immunotherapy between 1994 and 2009 were extracted from a
representative, commercially available database (the PHARMO institute, The Neth-
erlands). Data included drug name, type of allergen, amount of drug prescribed,
route of administration, type of prescribing physician, pharmacy visit date, socio-
economic status (SES), sex, age, pharmacy costs and revenues. Compliance was
defined as the number of late pharmacy visits, persistence was defined as the total
duration of treatment of at least three years. Time to treatment discontinuation
was analyzed using Kaplan-Meijer curves and Cox proportional hazard models.
RESULTS: A total of 48% of SLIT users and 37% of SCIT users discontinued therapy
before the first year, and 23% of SLIT users and 37% of SCIT users continue immu-
notherapy for at least three years. SLIT is predominantly prescribed by GPs, and
SCIT by allergologists. 2.6 late pharmacy visits were recorded per patient (SD 2.2).
Sex was not a significant predictor of persistence, but higher age, SES, and a rural
place of residence were. Nonpersistent behavior is associated with drug costs of
over 50M euros over the observation period. CONCLUSIONS: A significant differ-
ence in persistence exists between users of SLIT and SCIT in favor of the latter. The
high costs associated with non-persistence ask for both patient and doctor educa-
tion and warrants the use of compliance devices.
AD4
HEALTH OUTCOMES AS A FUNCTION OF INTENTIONAL AND UNINTENTIONAL
NON-ADHERENCE AMONG ELEVEN COSTLY CONDITIONS IN THE EU
Goren A1, Gupta S2, Dibonaventura MD1
11Kantar Health, New York, NY, USA, 22Kantar Health, Princeton, NJ, USA,
OBJECTIVES: Patient non-adherence to medications is associated with poorer
health status; yet, intentional (e.g., purposefully skipping doses) and uninten-
tional (e.g., forgetting) non-adherence can reflect distinct patient characteris-
tics. This study investigates the burden of intentional (INA) or unintentional
(UNA) nonadherence among eleven costly chronic conditions. METHODS: EU
2010 National Health and Wellness Survey data were used, including 19,279 (of
57,805) respondents who reported taking prescription medication for any of these
conditions: asthma, pain, congestive heart failure (CHF), COPD, diabetes, hyperten-
sion, depression, bipolar disorder, peripheral vascular disease (PVD), transient
ischemic attack (TIA), and stroke. Morisky Medication Adherence Scale items were
summed to create INA (“stop taking medicine when feeling better” and “. . .when
feeling worse”) and UNA (“forget to take medicine” and “careless about taking
medicine”) scores ranging from 0_adherence (reference) to 1_moderate and 2_high
nonadherence. Generalized linear models predicted health utilities (scored from
the SF-12v2) from INA or UNA, controlling for sociodemographic characteristics
and comorbidities. RESULTS:Among those taking medication for asthma (n_3147),
pain (n_6605), CHF (n_248), COPD (n_584), diabetes (n_3062), hypertension (n_8821),
depression (n_3714), bipolar disorder (n_240), PVD (n_106), TIA (n_287), or stroke
(n_356), 49.7% were male, mean age was 52.9 years (SD_15.0), and 32.3% and 30.8%
exhibited some INA and UNA, respectively (rINA/UNA_0.34, p_0.001). Across con-
ditions, adjusting for covariates, high (b_-0.040) and moderate (b_-0.028) INA was
associated with lower health utilities, as was high UNA (b_-0.017), all p_0.001. This
pattern was significant for high non-adherence in diabetes (INA: b_-0.058; UNA:
b_-0.023) and hypertension (INA: b_-0.054; UNA: b_-0.032), p_0.01; it was on average
non-significantly negative within other conditions, but significantly positive in
pain and PVD. CONCLUSIONS: These results suggest INA may have a stronger
negative impact on health status than UNA, which can help guide adherence-
improving intervention strategies. The results also highlight disease areas in which
interventions may yield better outcomes.
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